Related Experiment Videos

Ctla-4 expression and polymorphisms in lung tissue of patients with diagnosed non-small-cell lung cancer

Adam Antczak1, Dorota Pastuszak-Lewandoska, Paweł Górski

  • 1Department of General and Oncological Pulmonology, 1st Chair of Internal Diseases, Medical University of Lodz, Łódź, Poland.

Biomed Research International
|August 13, 2013
PubMed

Insights

Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene expression and polymorphisms in non-small-cell lung cancer (NSCLC) tissue were analyzed. Increased CTLA-4 expression correlated with specific genotypes and tumor size, suggesting a role in NSCLC development.

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a key regulator of T-cell activation and the antitumor immune response.
  • CTLA-4 polymorphisms and altered expression are linked to various cancers, but data from tumor tissue is limited.
  • Understanding CTLA-4 in non-small-cell lung cancer (NSCLC) tissue is crucial for cancer immunology research.

Purpose of the Study:

  • To investigate the association between CTLA-4 gene expression, specific polymorphisms (+49A/G, -318C/T), and non-small-cell lung cancer (NSCLC) tissue.
  • To explore the relationship between CTLA-4 variants, gene expression, and clinicopathological features like tumor size.
  • To compare CTLA-4 genotype distributions between NSCLC tumor tissue and corresponding blood samples.

Main Methods:

  • Real-time PCR was used to assess CTLA-4 gene expression in NSCLC tissue.
  • TaqMan probes were employed to analyze CTLA-4 polymorphisms (+49A/G [rs231775] and -318C/T [rs5742909]).
  • Genotype distributions were compared between tumor and blood samples.

Main Results:

  • Elevated CTLA-4 expression was detected in most NSCLC patients.
  • Increased CTLA-4 expression significantly correlated with the TT genotype (-318C/T) and larger tumor size (T3+T4).
  • The G allele and GG genotype (+49A/G) were significantly associated with increased NSCLC risk. Significant genotype differences were observed between tumor and blood samples.

Conclusions:

  • CTLA-4 gene expression and specific polymorphisms in NSCLC tissue are linked to tumor progression and risk.
  • Genotype variations between tumor and blood highlight the complex functionality of CTLA-4 in cancer tissue.
  • These findings contribute to understanding CTLA-4's role in the NSCLC immune microenvironment.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...